Overview

A Study of LY3200882 in Participants With Solid Tumors

Status:
Active, not recruiting
Trial end date:
2022-12-30
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate the safety of the study drug known as LY3200882 in participants with solid tumors.
Phase:
Phase 1
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Gemcitabine
Paclitaxel